Results 81 to 90 of about 19,899 (238)

The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling.

PLoS ONE, 2012
Mutations in leucine-rich repeat kinase 2 (LRRK2) are strongly associated with late-onset autosomal dominant Parkinson's disease. LRRK2 is highly expressed in immune cells and recent work points towards a link between LRRK2 and innate immunity.
Nicolas Dzamko, Francisco Inesta-Vaquera, Jiazhen Zhang, Chengsong Xie, Huaibin Cai, Simon Arthur, Li Tan, Hwanguen Choi, Nathanael Gray, Philip Cohen, Patrick Pedrioli, Kristopher Clark, Dario R Alessi   +12 more
doaj   +1 more source

S100A9 promotes pulmonary arterial hypertension by regulating mitochondria–endoplasmic reticulum interaction‐mediated inflammatory injury of endothelial cells

Interdisciplinary Medicine, EarlyView.
Macrophage‐derived S100 calcium‐binding protein A9 (S100A9) promotes the pathological progression of pulmonary arterial hypertension (PAH). S100A9 upregulates the interaction between signal‐transducing adaptor protein 2 and leucine‐rich repeat kinase 2, thereby regulating mitochondria–endoplasmic reticulum (ER) contact.
Chen Gong, Long Chen, Yiting Zhao, Xiaohe Wang, Qiang Yuan, Xiaofeng Fang, Liuyi Li, Yinbo Xu, Shumei Jiang, Guangwen Xu, Ke Meng, Delong Wang, Kangli Cao, Jianlong Sheng, Liling Guo, Shichun Shen   +15 more
wiley   +1 more source

The general LRRK2 interactome.

, 2023
A) Nodes (n = 407) represent LRRK2 interactors that were with FS > 2 and were reviewed by the UniprotKB. Node fill colour and node size are weighted on the final score (FS). Larger size and darker colour indicate higher FS.
Claudia Manzoni (204029), Patrick A. Lewis (8964842), Ruth C. Lovering (8964839), Kirsten Harvey (3682876), Valentina Escott-Price (577023), Yibo Zhao (1604110), Nikoleta Vavouraki (8964836)   +6 more
core   +1 more source

Clinical features and progression of Parkinson's disease with LRRK2 variants: A prospective study

Annals of Clinical and Translational Neurology
Objective We established a prospective cohort study to investigate the differences in motor and non‐motor symptoms between idiopathic Parkinson's disease (IPD) and Parkinson's disease in carriers of leucine‐rich repeat kinase 2 (LRRK2) gene risk variants
Tingwei Song, Xiaoxia Zhou, Chunyu Wang, Heng Wu, Xinxiang Yan, Jifeng Guo, Beisha Tang, Lifang Lei, Qian Xu, Parkinson's Disease & Movement Disorders Multicenter Database and Collaborative Network in China (PD‐MDCNC)   +9 more
doaj   +1 more source

Socio‐Occupational Functioning after Subthalamic Deep Brain Stimulation in Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Socio‐occupational functioning in patients with Parkinson's disease (PD) treated with subthalamic nucleus deep brain stimulation (STN‐DBS) is not fully captured by standard motor and quality‐of‐life scales. Objectives To characterize patient‐reported socio‐occupational functioning after STN‐DBS and explore associated clinical and ...
Gabriele Imbalzano, Elisa Montanaro, Martina Giacchero, Claudia Ledda, Alberto Romagnolo, Mario Giorgio Rizzone, Leonardo Lopiano, Maurizio Zibetti   +7 more
wiley   +1 more source

Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. [PDF]

PLoS ONE, 2012
LRRK2, a Parkinson's disease associated gene, is highly expressed in microglia in addition to neurons; however, its function in microglia has not been evaluated.
Beomsue Kim, Myung-Soon Yang, Dongjoo Choi, Jong-Hyeon Kim, Hye-Sun Kim, Wongi Seol, Sangdun Choi, Ilo Jou, Eun-Young Kim, Eun-Hye Joe   +9 more
doaj   +1 more source

Caught in the act: LRRK2 in exosomes [PDF]

Biochemical Society Transactions, 2019
Abstract Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are a frequent genetic cause of late-onset Parkinson's disease (PD) and a target for therapeutic approaches. LRRK2 protein can influence vesicle trafficking events in the cytosol, with action both in endosomal and lysosomal pathways in different types of cells.
Shijie Wang, Andrew B. West
openaire   +2 more sources

LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons

Journal of Parkinson’s Disease, 2021
Background: Mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common cause of familial Parkinson’s disease (PD) and are also associated with genetic risk in idiopathic PD.
Michael X. Henderson, Lakshmi Changolkar, John Q. Trojanowski, Virginia M.Y. Lee   +3 more
doaj   +1 more source

Disease‐Duration–Specific Percentiles for Prospective Subtyping of Parkinson's Disease: A PPMI‐Based Study

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease (PD) is clinically heterogeneous, with variable progression rates that complicate clinical trial design. The data‐driven diffuse malignant (DM), intermediate (IM), and mild‐motor predominant (MMP) subtyping model has prognostic value but lacks disease duration–specific thresholds for prospective use in disease ...
Ahmed Negida, Nitai Mukhopadhyay, Brian D. Berman, Seyed‐Mohammad Fereshtehnejad, Matthew J. Barrett   +4 more
wiley   +1 more source

LRRK2 phosphorylates ArfGAP1, and ArfGAP1 enhances LRRK2 kinase activity.

, 2012
(A) In vitro kinase assay with [32P]-γ-ATP, recombinant WT, R1441C, G2019S or D1994A human LRRK2 (Δ970, residues 970–2527) and GST-tagged ArfGAP1.
Darren J. Moore (154952), Liliane Glauser (154950), Klodjan Stafa (154945), Philip J. Webber (185205), Andrew B. West (185211), Alzbeta Trancikova (154943)   +5 more
core   +1 more source